AG˹ٷ

STOCK TITAN

The Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements due to Overestimated Noncash Impairment Charges

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

The Joint Corp. (NASDAQ: JYNT) announced plans to restate its financial statements for full-year 2024 and Q1 2025 due to errors in calculating impairment charges for clinics held for sale. The restatement is expected to reduce the 2024 net loss by $2.2 million and increase Q1 2025 net income by $0.5 million, resulting in a cumulative $2.7 million increase in the carrying value of assets held for sale.

The company identified a misapplication of accounting guidance related to the valuation methodology for assets held for sale. While the restatement will not impact Adjusted EBITDA, cash positions, or restricted cash for either period, the company expects to report a material weakness in internal control over financial reporting and ineffective disclosure controls.

The Joint Corp. (NASDAQ: JYNT) ha annunciato l'intenzione di rivedere i propri bilanci per l'intero anno 2024 e il primo trimestre 2025 a causa di errori nel calcolo delle svalutazioni relative alle cliniche destinate alla vendita. La revisione dovrebbe ridurre la perdita netta del 2024 di 2,2 milioni di dollari e incrementare l'utile netto del primo trimestre 2025 di 0,5 milioni di dollari, con un aumento complessivo di 2,7 milioni di dollari nel valore contabile degli asset destinati alla vendita.

L'azienda ha rilevato un'applicazione errata delle linee guida contabili riguardanti la metodologia di valutazione degli asset destinati alla vendita. Sebbene la revisione non influenzerà l'EBITDA rettificato, la posizione di cassa o la liquidità vincolata in entrambi i periodi, la società prevede di segnalare una debolezza significativa nel controllo interno sulla rendicontazione finanziaria e un'efficacia insufficiente dei controlli di divulgazione.

The Joint Corp. (NASDAQ: JYNT) anunció planes para reexpresar sus estados financieros correspondientes al año completo 2024 y al primer trimestre de 2025 debido a errores en el cálculo de cargos por deterioro relacionados con clínicas en proceso de venta. Se espera que la reexpresión reduzca la pérdida neta de 2024 en 2,2 millones de dólares y aumente el ingreso neto del primer trimestre de 2025 en 0,5 millones de dólares, resultando en un incremento acumulado de 2,7 millones de dólares en el valor en libros de los activos en venta.

La compañía identificó una aplicación incorrecta de las normas contables relacionadas con la metodología de valoración de activos en venta. Aunque la reexpresión no afectará el EBITDA ajustado, la posición de efectivo ni el efectivo restringido en ninguno de los períodos, la empresa espera reportar una debilidad material en el control interno sobre la información financiera y controles de divulgación ineficaces.

The Joint Corp. (NASDAQ: JYNT)� 매각 예정 클리닉에 대� 손상차손 계산 오류� 인해 2024� 전체 � 2025� 1분기 재무제표� 정정� 계획� 발표했습니다. 이번 정정으로 2024� 순손실이 220� 달러 감소2025� 1분기 순이익이 50� 달러 증가하여, 매각 예정 자산� 장부가치가 � 270� 달러 증가� 것으� 예상됩니�.

회사� 매각 예정 자산 평가 방법론과 관련된 회계 지침의 오적용을 확인했습니다. 이번 정정은 조정 EBITDA, 현금 보유� 또는 제한 현금� 영향� 미치지 않지�, 회사� 재무 보고 내부 통제� 중대� 약점� 비효율적� 공시 통제� 보고� 것으� 예상합니�.

The Joint Corp. (NASDAQ: JYNT) a annoncé son intention de retraiter ses états financiers pour l'année complète 2024 et le premier trimestre 2025 en raison d'erreurs dans le calcul des charges de dépréciation liées aux cliniques destinées à la vente. Ce retraitement devrait réduire la perte nette de 2024 de 2,2 millions de dollars et augmenter le bénéfice net du premier trimestre 2025 de 0,5 million de dollars, entraînant une augmentation cumulée de 2,7 millions de dollars de la valeur comptable des actifs destinés à la vente.

La société a identifié une mauvaise application des normes comptables relatives à la méthodologie d'évaluation des actifs destinés à la vente. Bien que ce retraitement n'affectera pas l'EBITDA ajusté, la trésorerie ou la trésorerie restreinte pour ces périodes, la société prévoit de déclarer une faiblesse significative dans le contrôle interne de l'information financière ainsi que des contrôles de divulgation inefficaces.

The Joint Corp. (NASDAQ: JYNT) kündigte an, seine Finanzberichte für das Gesamtjahr 2024 und das erste Quartal 2025 aufgrund von Fehlern bei der Berechnung von Wertminderungsaufwendungen für zum Verkauf gehaltene Kliniken neu aufzustellen. Die Neubewertung wird voraussichtlich den Nettoverlust 2024 um 2,2 Millionen US-Dollar reduzieren und den Nettogewinn im ersten Quartal 2025 um 0,5 Millionen US-Dollar erhöhen, was zu einer kumulierten Steigerung des Buchwerts der zum Verkauf gehaltenen Vermögenswerte um 2,7 Millionen US-Dollar ü.

Das Unternehmen stellte eine fehlerhafte Anwendung der Rechnungslegungsrichtlinien bezüglich der Bewertungsmethodik für zum Verkauf gehaltene Vermögenswerte fest. Obwohl die Neubewertung das bereinigte EBITDA, die Liquiditätsposition oder das gebundene Bargeld in beiden Zeiträumen nicht beeinflusst, erwartet das Unternehmen, eine wesentliche Schwäche der internen Kontrolle über die Finanzberichterstattung sowie ineffektive Offenlegungskontrollen zu melden.

Positive
  • Net loss for 2024 will decrease by $2.2 million due to correction of overestimated impairment charges
  • Q1 2025 net income will increase by $0.5 million
  • No impact on Adjusted EBITDA, cash, cash equivalents, or restricted cash positions
Negative
  • Material weakness identified in internal control over financial reporting
  • Disclosure controls and procedures were deemed ineffective
  • Company needs to implement remedial measures to address control weaknesses

Insights

The Joint Corp's restatement will improve financial results by reducing 2024 losses by $2.2M and increasing Q1 2025 income by $0.5M due to accounting errors.

The Joint Corp is correcting a significant accounting error related to how they calculated impairment charges on assets held for sale. This restatement will actually improve their financial picture - reducing their 2024 net loss by approximately $2.2 million and increasing their Q1 2025 net income by about $0.5 million.

What happened here is a technical accounting issue. The company misapplied accounting guidance on how to value clinics classified as "held for sale" in their discontinued operations. The correction increases the carrying value of these assets by $2.7 million cumulatively through Q1 2025.

Importantly, this restatement has no impact on Adjusted EBITDA for either period, which is often viewed as a better indicator of operational performance. There's also no effect on cash positions, meaning this is purely a non-cash accounting adjustment.

The company has acknowledged this error will likely result in declaring a material weakness in internal controls over financial reporting, meaning their financial oversight systems need improvement. They're implementing remedial measures to address these weaknesses.

For investors, this restatement is actually favorable from a numbers perspective - the company's performance was better than originally reported. However, the need for a restatement and the identification of control weaknesses raises governance concerns about financial reporting quality and oversight at the company.

- Expects to reduce 2024 net loss and increase carrying value of assets held for sale
by approximately $2.2 million -
- Expects to increase first quarter 2025 net income by approximately $0.5 million, resulting in a cumulative increase in carrying value of assets held for sale by approximately $2.7 million -
- No change to 2024 or first quarter 2025 Adj. EBITDA -

SCOTTSDALE, Ariz., July 30, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announced the Company intends to restate previously issued audited financial statements as of and for the year ended December 31, 2024 contained in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 14, 2025 and the unaudited interim financial statements as of and for the quarter ended March 31, 2025 contained in the Quarterly Report on Form 10-Q filed with the SEC on May 9, 2025 (collectively, the “Previously Issued Financial Statements�) related to the impairment on the carrying values of company-owned or managed clinics classified as held for sale and included in discontinued operations.

Background

The errors relate to previously recorded impairment on the carrying values of company-owned or managed clinics held for sale and included in discontinued operations. Specifically, there was a misapplication of accounting guidance related to the valuation methodology for certain assets held for sale. Upon further evaluation, the Company determined that the original methodology applied was not consistent with generally accepted accounting principles, and adjustments are necessary to accurately present the Company’s financial position and results of operations.

Estimated Impact

The Company is in the process of but has not yet completed, its determination of the degree to which these errors will have an effect on the Company’s Previously Issued Financial Statements. Based on its review to date, the following preliminary estimated impact of the identified errors on the Previously Issued Financial Statements are the Company’s current estimates of the impact and are subject to change in connection with the completion of the restatements.

For the year ended December 31, 2024, the correction for the impairment on assets held for sale is expected to result in a reduction of previously reported loss from discontinued operations before income taxes of approximately $2.2 million. As a result, the total impact of this adjustment for the year is an estimated $2.2 million decrease in net loss for the year ended December 31, 2024, and an estimated $2.2 million increase in the carrying value of assets held for sale reported in discontinued operations current assets for the period then ended.

This adjustment is not expected to have any impact on Adjusted EBITDA for the year ended December 31, 2024, nor on cash, cash equivalents, or restricted cash as of that date.

For the period ended March 31, 2025, the correction for the impairment on assets held for sale is expected to result in an increase of previously reported income from discontinued operations before income taxes of approximately $0.5 million. As a result, the total impact of these adjustments is an estimated $0.5 million in net income for the quarter ended March 31, 2025 and an estimated cumulative $2.7 million increase in the carrying value of assets held for sale reported in discontinued operations current assets for the period then ended.

The adjustment is not expected to have any impact on Adjusted EBITDA for the quarter ended March 31, 2025, or on cash, cash equivalents, or restricted cash as of that date.

The Company is also evaluating the impact of the identified error on its internal control over financial reporting and disclosure controls and procedures. Although the evaluation is not yet complete, the Company expects it will result in a material weakness in the Company’s internal control over financial reporting and will conclude that its disclosure controls and procedures were ineffective during the applicable periods related to the Previously Issued Financial Statements. The Company continues to evaluate and implement remedial measures to address such material weaknesses.

Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements, including expectations about the timing of the completion and filing of the 10-K/A and 10-Q/A, the anticipated impact and effects of the errors on the Previously Issued Financial Statements, and the impact of the identified errors on our internal control over financial reporting and disclosure controls and procedures, are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs, may lead to reduced discretionary spending, all of which may negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and the factors described in our filings with the SEC, including in the section entitled “Risk Factors� in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 14, 2025 and subsequently-filed current and quarterly reports. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With over 950 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times� annual “Top 400� and “Fast & Serious� list of 40 smartest growing brands. Entrepreneur named The Joint “No. 1 in Chiropractic Services,” and is regularly ranked on the publication’s “Franchise 500,” the “Fastest-Growing Franchises,� the “Best of the Best� lists, as well as its “Top Franchise for Veterans� and “Top Brands for Multi-Unit Owners.”�SUCCESS named the company as one of the “Top 50 Franchises� in 2024. The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit . To learn about franchise opportunities, visit .

The Joint Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Media Contact:
Margie Wojciechowski, The Joint Corp.,

Investor Contact:
Kirsten Chapman, Alliance Advisors IR, 415-433-3777,


FAQ

What is the reason for JYNT's financial restatement in 2024 and Q1 2025?

The Joint Corp. is restating financials due to overestimated noncash impairment charges related to the valuation methodology for certain assets held for sale, which was found to be inconsistent with generally accepted accounting principles.

How much will The Joint Corp's 2024 financial results improve after the restatement?

The restatement will reduce JYNT's 2024 net loss by approximately $2.2 million and increase the carrying value of assets held for sale by the same amount.

Will JYNT's restatement affect its Adjusted EBITDA or cash position?

No, the restatement will have no impact on Adjusted EBITDA, cash, cash equivalents, or restricted cash for either 2024 or Q1 2025.

What internal control issues were identified at The Joint Corp?

The company identified a material weakness in internal control over financial reporting and concluded that its disclosure controls and procedures were ineffective during the periods requiring restatement.

How will The Joint Corp's Q1 2025 results change after the restatement?

Q1 2025 results will show an increase in net income of approximately $0.5 million and a cumulative $2.7 million increase in the carrying value of assets held for sale.
Joint Corp

NASDAQ:JYNT

JYNT Rankings

JYNT Latest News

JYNT Latest SEC Filings

JYNT Stock Data

174.15M
13.95M
2.21%
74.82%
2.71%
Medical Care Facilities
Patent Owners & Lessors
United States
SCOTTSDALE